Alnylam Pharmaceuticals, Inc. (FRA:DUL)

Market Cap	45.24B
Revenue (ttm)	2.74B
Net Income (ttm)	37.13M
Shares Out	n/a
EPS (ttm)	0.28
PE Ratio	1,218.33
Forward PE	37.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	340.40
Previous Close	342.70
Day's Range	339.40 - 348.40
52-Week Range	198.70 - 423.00
Beta	n/a
RSI	41.94
Earnings Date	Feb 20, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 2,230
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DUL

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD